Bioatla reports first quarter 2025 financial results and highlights recent progress

San diego, may 06, 2025 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the first quarter ended march 31, 2025 and provided highlights on its clinical programs.
BCAB Ratings Summary
BCAB Quant Ranking